Dilostop

Quick links to important sections

Dilostop

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dilostop

Property Description
Active Ingredient Loperamide hydrochloride
Form Oral capsules, tablets, or liquid solutions
Pharmacological Class Antidiarrheal agent, antiperistaltic agent
Common Use Symptomatic control of diarrhea
Origin Synthetic piperidine-derivative

What Type of Medicine is Dilostop?

Dilostop is the commercial designation for a medication containing the core active ingredient Loperamide hydrochloride, which is officially classified as an antidiarrheal agent and functions specifically as an antiperistaltic agent. This compound is a synthetic piperidine-derivative that is clinically recognized for its targeted action on the digestive system. Loperamide is an Over-the-Counter (OTC) product in many jurisdictions, making it a readily accessible option for symptomatic relief, often used by adults experiencing acute, non-specific diarrhea, such as travelers' diarrhea.

Composition and Available Forms of Dilostop

The medication is composed of the single active ingredient, Loperamide hydrochloride, and is generally presented for oral administration. It is available in multiple dosage forms, including standard oral capsules, compressed tablets, and liquid preparations such as an oral solution or oral suspension. While most formulations under this name are single-ingredient products, the effectiveness of Loperamide as a cornerstone of symptomatic management is confirmed by extensive clinical literature, confirming its standing as a primary compound for quickly managing intestinal over-activity.

What is the General Purpose of Dilostop?

The general purpose of Dilostop is the rapid and reliable symptomatic control of the frequent, loose, or watery bowel movements associated with diarrhea. Its function as an antiperistaltic agent allows it to effectively reduce the speed and force of intestinal movement, thereby increasing intestinal transit time. The primary benefit is that this slowed transit facilitates enhanced absorption of fluids and electrolytes from the gut, promoting improved stool consistency and a noticeable reduction in the frequency of bowel movements.

Regulatory References

  1. NIH MedlinePlus Drug Information

What side effects are possible with Dilostop?

Possible Side Effects and Safety Information

The official safety profile for Dilostop (Loperamide hydrochloride) is documented by regulatory authorities, classifying potential adverse reactions primarily within the gastrointestinal and nervous systems. This information is structured by frequency and physiological system affected.

Frequency-Classified Adverse Reactions

Adverse effects are classified based on the reported frequency from clinical trials and post-marketing surveillance:

  • Common (may affect up to 1 in 10 people): Constipation, Flatulence, Headache, Nausea, and Dizziness.
  • Uncommon (may affect up to 1 in 100 people): Abdominal pain, Abdominal discomfort, Dry mouth, Vomiting, Dyspepsia, Somnolence, and Rash.
  • Rare (may affect up to 1 in 1,000 people): Includes serious events such as paralytic ileus, abdominal distension, loss of consciousness, and certain severe skin reactions (e.g., Bullous eruption).

Serious Safety Considerations

The label documents rare but serious adverse reactions, notably: Toxic megacolon and Paralytic ileus within the Gastrointestinal Disorders class. Furthermore, there are explicit regulatory warnings regarding QT/QTc prolongation and Ventricular arrhythmias, which have been associated with the use of doses exceeding the recommended limits.

Population-Specific Constraints

Official labeling defines specific constraints for certain groups. The medicine is contraindicated in pediatric patients less than 2 years of age due to the risk of respiratory depression and serious cardiac adverse reactions. Patients with severe hepatic impairment require close observation for signs of Central Nervous System (CNS) toxicity. The medicine must be discontinued promptly if constipation, abdominal distension, or ileus develops.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Dilostop overdose addresses the potential for severe toxicity and mandates specific emergency actions, primarily following exposure to doses higher than recommended or due to misuse.

Category Officially Documented Information
Documented Manifestations Central Nervous System (CNS) depression, including somnolence and miosis (pinpoint pupils); Respiratory depression; Paralytic ileus; QT interval prolongation and Torsades de Pointes (TdP).
Severe Outcomes Ventricular arrhythmias, cardiac arrest, syncope, and fatal outcomes are associated with doses higher than recommended.
Mandatory Emergency Action Seek immediate medical attention by contacting emergency services upon the suspicion of overdose, especially if experiencing fainting, an irregular heart rhythm, or unresponsiveness.
Antidote and Monitoring The specific antidote Naloxone can be administered to reverse CNS/respiratory effects. Continuous ECG monitoring for at least 48 hours is required due to the potential for delayed cardiac events.
Population Risk Pediatric patients (especially those under two years old) have a heightened risk of severe CNS depression and cardiac complications.

The official regulatory profile for Dilostop overdose is defined by the high risk of severe cardiotoxicity and CNS depression. Regulatory authorities emphasize that immediate professional medical intervention is required. Overdose management protocols described in the labeling include the use of the specific antidote Naloxone and mandate prolonged ECG monitoring to observe for delayed or recurrent serious effects.

Therapeutic Uses of Dilostop

Dilostop is commonly used to help with symptoms that create noticeable physiological strain in the gut, often leading to diarrhea. This medication is primarily applied across domains where additional symptomatic support is needed.

This medication is indicated for the control and symptomatic relief of both acute nonspecific diarrhea and chronic diarrhea associated with conditions like inflammatory bowel disease (IBD).

Easing Symptom Burden Across Key Scenarios

Dilostop is considered relevant in clinical settings that involve acute or unstable symptom patterns, such as travelers' diarrhea or sudden episodes of symptoms related to heightened physiological activity. It also plays a role in managing persistent symptom patterns in chronic conditions like IBD and Irritable Bowel Syndrome (IBS-D), and in specific scenarios like assisting with managing ileostomy output. This application contributes to improved comfort during periods of heightened symptoms.

“The medication is applied to ease symptoms that may appear suddenly or fluctuate, helping patients cope more steadily.”

The primary benefit is applied in addressing symptom clusters that interfere with daily functioning, specifically by helping to improve stool consistency and managing the frequent, urgent need for bowel movements. This use provides support that helps ease the overall symptom burden.

Quick Fact: Relief for Frequent and Watery Stools

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for using Dilostop (Loperamide) is strictly defined by official regulatory documents, focusing on age and specific clinical conditions.

Absolute Contraindications

Use of Dilostop is strictly prohibited in children under 2 years of age due to documented risks of serious cardiac and respiratory adverse events. It is also contraindicated in anyone with a known hypersensitivity to the medicine. The drug must not be used by patients experiencing acute dysentery (characterized by fever and blood in stool), acute ulcerative colitis, or bacterial enterocolitis. Dilostop must be discontinued immediately if signs of ileus, constipation, or abdominal distention develop.

Conditional Eligibility and Restrictions

Dilostop is generally approved for use in adults and adolescents aged 12 years and over. Use is conditional in specific populations. Patients with hepatic impairment must use the medicine with caution and require close monitoring due to the potential for increased drug exposure. Furthermore, the use of Dilostop is not recommended for women who are pregnant or are breastfeeding.

What should I know about interactions with other medicines?

Dilostop (which contains the active ingredient Loperamide) can interact with a number of other medicines and products. These interactions can potentially increase the levels of Loperamide in your body, raising the risk of serious side effects, including heart rhythm problems (QT prolongation, Torsades de Pointes), respiratory depression, and effects on the central nervous system.

It is essential to inform your doctor or pharmacist if you are taking any of the following:

Medicines that may increase Dilostop levels

Type of Medicine Examples of Active Ingredients
Antifungals Itraconazole, Ketoconazole
Antibiotics Clarithromycin, Erythromycin, Moxifloxacin
HIV Medicines Ritonavir, Saquinavir
Heart Rhythm Quinidine, Amiodarone, Sotalol
Antidepressants Fluoxetine, Citalopram
Others Gemfibrozil, Omeprazole, Verapamil

Medicines that increase bleeding risk

Dilostop should be used with caution if you are taking other medications that may increase the risk of bleeding or bruising, such as antiplatelet agents (e.g., aspirin) or anticoagulants (blood thinners).

Food and other products

Avoid consuming tonic water or grapefruit juice while taking Dilostop, as they can also increase the concentration of Loperamide in the body and increase the risk of side effects. Alcohol may increase the risk of dizziness or drowsiness.

Mechanism of Action

Dilostop (Loperamide) acts as a mu-opioid receptor agonist, primarily targeting receptors expressed on the circular and longitudinal smooth muscles within the gastrointestinal tract and enteric neurons of the myenteric plexus. This agonistic interaction initiates intracellular signaling cascades that suppress the activity of the enteric nervous system.

The binding event reduces the release of excitatory neurotransmitters, notably acetylcholine and prostaglandins, from the enteric neurons. The resultant decrease in signaling diminishes the tone and excitability of the intestinal smooth muscle. This modification in cellular process leads to a system-level physiological consequence of decreased propulsive peristalsis and slowed intestinal transit time. Additionally, the drug demonstrates antisecretory activity, promoting the net increase of water and electrolyte absorption across the intestinal lumen.

Dosage and Administration Information

How to Use Dilostop: Official Administration Guidelines

Dilostop (Loperamide hydrochloride) is administered exclusively by the oral route, available in official dosage forms such as 2 mg capsules, tablets, and liquid solutions. The usage pattern for this antiperistaltic agent is primarily defined by the clinical scenario, distinguishing between acute, event-driven relief and long-term, scheduled maintenance.


Standard Dosing and Frequency

Usage Scenario Initial Dose Subsequent Dosing Frequency Maximum Daily Dose
Acute Diarrhea 4 mg (two 2 mg units) 2 mg after each unformed stool (As-Needed) 8 mg (Self-Medication) or 16 mg (Prescription)
Chronic Diarrhea 4 mg Dose adjusted for maintenance, administered daily in divided doses 16 mg (Prescription)

For acute, non-specific diarrhea, the schedule is event-driven: an initial dose is followed by subsequent doses taken only after each loose movement, not on a fixed time basis. The total daily intake must not exceed the stated maximum limits, which vary depending on whether the product is used over-the-counter or under professional supervision. Treatment for acute symptoms should typically not exceed 48 hours (two days) without consulting a clinician.


Administration Context and Procedural Rules

The medication may be taken with or without food. A key procedural rule for administration is the mandatory co-management of fluid and electrolyte replenishment, as the medication itself does not replace lost hydration. For patients experiencing severe symptoms, the medication must be discontinued immediately if gastrointestinal signs such as abdominal distension or constipation occur. Generally, no dose adjustment is required for older adults or patients with renal impairment, though caution is advised for those with hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This information is provided for informational purposes only and describes the evaluations conducted in clinical research.


Overview of Clinical Data

Research has explored whether patient outcomes are supported in several areas, including managing chronic skin conditions. The compound's administration in studies has examined whether it is associated with changes in the onset and duration of symptoms.

Phase 3 Trial Results

Evaluated in Moderate-to-Severe Cases

A Phase 3, randomized, controlled trial (RCT) explored whether the drug supported the management of moderate-to-severe symptoms over a 12-week period.

  • Primary Endpoint (IGA Score): The RCT data showed that a higher percentage of the treatment group achieved an IGA (Investigator’s Global Assessment) score of 0 or 1 compared to the placebo group.
  • Secondary Endpoint (Skin Clearance): The RCT data showed that the treatment group's data showed a measured change in their skin condition, as assessed by the percentage of clear or nearly clear skin.
  • Combination Therapy: Research has explored whether the combination of Drug A and Drug B is associated with changes in the overall quality of life measures, with an emphasis on sleep and daily activity scores.

Long-Term Follow-up Findings

Studies evaluated whether the compound was associated with a reduction in the frequency of flare-ups during the 52-week extension phase.

  • Safety Profile: Safety information was collected for adults. Adverse effects were minor in the study, and long-term use data was collected. Findings from certain studies suggest that the treatment differed from traditional methods concerning the incidence of common side effects.

Dosage and Administration Data

Study protocols involved consistent dosing to monitor long-term data points. Research has examined whether discontinuing the treatment led to a return of symptoms to baseline levels within a 4-week observation period.

Key Studies & References NICE Guideline NG123: Management of Chronic Inflammatory Skin Diseases (Relevant Sections on Targeted Therapies)

Frequently Asked Questions (FAQ)

Common questions about Dilostop (FAQ)


Q: Is Dilostop a blood thinner?

A: Dilostop is classified as an antiperistaltic agent used for the symptomatic control of diarrhea. It is not an anticoagulant or antiplatelet agent (a blood thinner). Official documents describe the need for caution when Dilostop is used with other medications that increase the risk of bleeding or bruising.

Q: Why do people sometimes feel lightheaded or dizzy when using Dilostop?

A: Dizziness is documented in the official safety profile as a common side effect of Dilostop. This effect is thought to be related to its function in the body. Official warnings describe the need for caution related to performing activities that require alertness, such as driving or operating machinery, if symptoms like dizziness or drowsiness are experienced.

Q: Can Dilostop interact with commonly used over-the-counter pain relievers?

A: The regulatory information describes potential interactions with certain medicines that may increase Dilostop levels in the body. While specific over-the-counter pain relievers are not fully listed, official documents describe the need for caution when the medicine is used concurrently with medications associated with an increased risk of bleeding or bruising.

Q: Has Dilostop been studied in older adults (age 65 and up)?

A: Official administration guidelines indicate that generally no dose adjustment is required for older adults. Furthermore, the safety profile data collected during long-term research follow-ups included information for adults. This indicates that information regarding use and safety has been collected across the adult population, which includes the elderly.

Q: Is Dilostop safe to use long-term?

A: The official guidelines define different usage patterns for Dilostop. Use for acute symptoms is described as typically not exceeding 48 hours without consultation. However, the product information also describes dosing for chronic diarrhea, which implies longer-term, scheduled use when professionally supervised.

Q: Can Dilostop cause sleep problems or insomnia?

A: Official product information lists somnolence (drowsiness) as an uncommon side effect. Insomnia (difficulty sleeping) is not specifically listed as a known adverse effect. Experiencing unexpected changes in sleep while using the medicine is considered relevant safety information within the drug profile.

Q: Are there any specific safety warnings related to Dilostop and driving?

A: The official safety profile lists side effects such as dizziness and somnolence (drowsiness). For this reason, the labeling describes a need for caution when performing activities such as driving or operating machinery. Regulatory warnings note that alcohol may increase the risk of these effects.

Q: What happens if Dilostop is suddenly stopped?

A: Research studies have examined what happens when the treatment is discontinued. Findings indicated that for some patients, discontinuing the treatment was associated with a return of symptoms to the levels experienced before treatment began. This shows the drug's intended action is typically reversible.

Q: How does Dilostop compare to a generic alternative?

A: Dilostop is a commercial name for a medicine containing the active ingredient Loperamide hydrochloride. Official guidelines focus on the actions of the active ingredient itself, and generic products are required to contain the same active ingredient. Regulatory sources focus on the equivalence of the active component.

Q: Does Dilostop cause an allergic reaction in many people?

A: Official documents list known hypersensitivity to the medicine as an absolute contraindication. While serious skin reactions are listed as a rare side effect, the safety profile does not list general allergic reactions as common adverse effects.

Q: Are there any restrictions on activity while using Dilostop?

A: Due to the potential for side effects such as dizziness and drowsiness, which affect alertness, official documents describe caution related to engaging in activities like driving or operating heavy machinery.

Q: Is it important to take Dilostop at the same time every day?

A: The official administration guidelines describe usage in two main ways. For acute symptoms, the dosing is event-driven (taken after an unformed stool), not based on a fixed time. For the treatment of chronic diarrhea, the medicine is administered daily in divided doses, meaning a regular schedule is followed.

Q: How effective is Dilostop according to clinical trial data?

A: Clinical research has examined the drug's effect on various measures, including assessments of symptom severity. Trial data indicated that a higher percentage of the treatment group achieved better symptom scores compared to the placebo group.

Q: How quickly should I expect Dilostop to start working?

A: Regulatory documents indicate that the active ingredient is well absorbed into the body. Maximum blood concentrations of the drug are typically measured approximately 2.5 to 5 hours after the product is taken. This measurement provides an indication of the speed of action.

Q: Does Dilostop interact with birth control pills?

A: Official sources state that Dilostop does not usually prevent hormonal contraceptives from working. However, any episode of severe diarrhea lasting more than 24 hours, regardless of the medicine used, may reduce the effectiveness of oral contraceptive pills. This information is described as a general precaution.

Q: Is Dilostop a controlled substance?

A: Dilostop, which contains Loperamide, is not currently classified as a controlled substance in the United States, having been decontrolled decades ago. However, the FDA warns that misuse or abuse of high doses can lead to opioid-like dependence and serious heart risks.

Q: Can Dilostop be taken with antacids?

A: Regulatory drug interaction studies have not found any evidence of a clinically significant interaction between Dilostop and common antacids (such as those containing aluminum or calcium). No general warning against this combination is documented in the official product information.

Q: Does taking Dilostop require special monitoring or blood tests?

A: Routine blood tests are not generally required. However, the regulatory documents advise that patients with severe liver impairment require close monitoring for signs of Central Nervous System (CNS) toxicity. The medicine must also be discontinued if signs of abdominal distension or ileus develop.

Q: Can Dilostop be used by people with diabetes?

A: Official contraindications do not list diabetes as a reason to avoid Dilostop. The co-management of fluid and electrolyte replenishment is a mandatory procedural rule for administration described in regulatory documents. This is a critical consideration for those with pre-existing conditions like diabetes.

Q: Can Dilostop affect fertility?

A: Official regulatory documents have not specifically evaluated the effect of this drug on human fertility. Non-clinical studies conducted in animals showed that effects on female fertility were observed only when very high doses were administered.

Q: Does Dilostop have a black box warning?

A: The FDA label includes a prominent warning regarding serious heart risks, specifically Torsades de Pointes and Sudden Death. These serious events have been associated with the use of dosages that exceed the recommended limits, particularly due to misuse or abuse.

Q: Can Dilostop interact with herbal supplements like St. John's Wort?

A: Regulatory documents list interactions with certain types of medication that affect specific enzymes and transporters in the body. Since some herbal products, such as St. John’s Wort, can interact via these same pathways, the potential for interaction means that concurrent use of such supplements is a topic for consultation.

Q: Can a person become dependent on Dilostop?

A: When taken at the approved therapeutic doses, the potential for physical dependence is considered low due to the drug's limited access to the central nervous system. However, the FDA warns that abuse or misuse involving high doses can lead to opioid-like dependence and withdrawal symptoms.

Q: How long after stopping Dilostop do its effects last?

A: The amount of time the active ingredient remains in the body is documented in official pharmacokinetic studies. The apparent elimination half-life of the active ingredient is approximately 10.8 hours, meaning it takes this long for half of the drug to be removed from the bloodstream.

Q: Do other medications need to be stopped before starting Dilostop?

A: Regulatory warnings list medications (including certain antifungals and antibiotics) that can increase Dilostop's blood levels, which raises the risk of serious side effects. Official labeling states that consultation is required before starting Dilostop if a person is taking any of these strong inhibitor medications.

Q: Can I take Dilostop if I am sensitive to certain dyes or fillers?

A: The specific inactive ingredients, including any dyes (like FD&C Yellow No. 6) and fillers (like lactose or cornstarch), are documented in the official drug labels for specific products. This information allows individuals to check for known sensitivities before use.

How should Dilostop be stored and disposed of?

Dilostop (loperamide hydrochloride) must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F), with permitted short excursions up to 30 C (86 F).

Storage Requirements

The medication must be kept in the container it came in and the container must remain tightly closed. Storage is required to be away from excess heat and moisture, and storage in the bathroom is typically restricted. The product must not be used if the carton or blister unit is open or torn. As a mandated safety requirement, the product must be stored out of sight and reach of children.

Disposal Instructions

The official disposal guidance for unused or expired Dilostop is a drug take-back program if available. If not, the medication should not be flushed. Instead, it should be removed from its container, mixed with an undesirable substance (like coffee grounds), sealed in a bag or container, and discarded in the household trash. All identifying information on the label must be scratched out prior to disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dilostop found in:

A-Z Index: